CD19 Antibody (CB19) - BSA Free

CD19 (Cluster of Differentiation 19), also known as B-lymphocyte surface antigen B4, is a type 1 transmembrane glycoprotein belonging to immunoglobulin (Ig) subfamily that serves as a biomarker for normal and neoplastic B cells (1,2). CD19 is a co-receptor for the B cell receptor (BCR) signaling complex and has a critical role in regulating B cell signaling and immune response (1,2). The CD19 protein contains an extracellular N-terminus containing two C2 Ig-like domains separated by a helical non-Ig domain, a single pass transmembrane domain, and a highly conserved cytoplasmic C-terminal domain (1,2). The human CD19 protein, encoded by the CD19 gene located on chromosome 16p11.2, is 556 amino acids (aa) in length with a calculated theoretical molecular weight (MW) of 61 kDa and an observed molecular weight of 95 kDa (1-3). CD19 associates with other molecules - CD21, CD81, and CD225 - to form the BCR co-complex, also called the CD19 complex, through CD21 binding to the complement C3d complex (1-3). Complement C3d bridges the BCR with the CD19 complex into lipid rafts of the plasma membrane (1-3). CD19 is capable of modulating B cell development through both BCR-dependent and -independent signaling (1-3). Upon BCR activation, the tyrosine residues of CD19's cytoplasmic tail recruits multiple kinases including Lyn, Vav, and PI3K, amplifying BCR-mediated immune signaling and B cell activation (1-3).

Considering the role of CD19 in BCR signaling and its expression in development from pre-B cells through plasma cells, it is understandable that CD19 dysfunction and abnormal expression is associated with numerous B cell malignancies and autoimmune disorders (1-5). CD19 expression is typically observed at relatively normal levels in B cell acute lymphoblastic leukemia (B-ALL) and chronic lymphoblastic leukemia (CLL) but is often reduced other types of lymphoma including diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) (1,2). On the other hand, CD19 expression is typically increased in autoimmune disorders such as systemic sclerosis (SSc) and multiple sclerosis (MS) as modeled by experimental autoimmune encephalomyelitis (EAE) (2). CD19 has become a therapeutic molecular target for the treatment of B cell lymphomas and autoimmune disorders using monoclonal antibodies (mAbs), bi-specific T cell engaging (BiTE) antibodies, and CD19-specific chimeric antigen receptor (CAR) T cells (1,2,4-6). Although anti-CD19 CAR T cell therapy has become the standard for the treatment of B cell malignancies, patients may experience relapse due to resistance mechanisms (6). Strategies to improve efficacy and limit relapse include combination of CAR T cell therapy with immune checkpoint inhibitors like anti-PD-1 (4,6).

References

1. Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1(1):36. https://doi.org/10.1186/2162-3619-1-36

2. Li X, Ding Y, Zi M, et al. CD19, from bench to bedside. Immunol Lett. 2017;183:86-95. https://doi.org/10.1016/j.imlet.2017.01.010

3. Wentink MWJ, van Zelm MC, van Dongen JJM, Warnatz K, van der Burg M. Deficiencies in the CD19 complex. Clin Immunol. 2018;195:82-87. https://doi.org/10.1016/j.clim.2018.07.017

4. Frigault MJ, Maus MV. State of the art in CAR T cell therapy for CD19+ B cell malignancies. J Clin Invest. 2020;130(4):1586-1594. https://doi.org/10.1172/JCI129208

5. Penack O, Koenecke C. Complications after CD19+ CAR T-Cell Therapy. Cancers (Basel). 2020;12(11):3445. https://doi.org/10.3390/cancers12113445

6. Bouziana S, Bouzianas D. Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy. Crit Rev Oncol Hematol. 2021;157:103096. https://doi.org/10.1016/j.critrevonc.2020.103096

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 2 confirmed species: Human, Mouse.

We have publications tested in 4 applications: FLOW, ICC/IF, In vitro, WB.

Showing Publications 1 - 10 of 11. Show All 11 Publications. Collapse Publications.

Publications using NBP2-25196	Applications	Species
Holla S, Prakhar P, Singh V et al. MUSASHI-Mediated Expression of JMJD3, a H3K27me3 Demethylase, Is Involved in Foamy Macrophage Generation during Mycobacterial Infection PLoS Pathog. PLoS Pathog. 2016-08-01 [PMID: 27532872] (Mouse) Details: This citation used the PE version of this antibody.		Mouse
Deaglio S, Vaisitti T, Billington R et al. CD38/CD19: a lipid raft-dependent signaling complex in human B cells Blood. 2007-06-15 [PMID: 17327405] (ICC/IF, WB, Human)	ICC/IF, WB	Human
Deaglio S, Vaisitti T, Bergui L et al. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival Blood. 2005-04-15 [PMID: 15613544] (ICC/IF, FLOW, Human)	ICC/IF, FLOW	Human
Deaglio S, Capobianco A, Bergui L et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells Blood. 2003-09-15 [PMID: 12763926] (ICC/IF, FLOW, Human)	ICC/IF, FLOW	Human
Musso T, Deaglio S, Franco L et al. CD38 expression and functional activities are up-regulated by IFN-gamma on human monocytes and monocytic cell lines J Leukoc Biol. 2001-04-01 [PMID: 11310847] (Human)		Human
Deaglio S, Canella D, Baj G et al. Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells Leuk Res. 2001-03-01 [PMID: 11226519]
Zilber MT, Gregory S, Mallone R et al. CD38 expressed on human monocytes: a coaccessory molecule in the superantigen-induced proliferation Proc Natl Acad Sci U S A. 2000-03-14 [PMID: 10706632] (Human)		Human
Morra M, Zubiaur M, Terhorst C et al. CD38 is functionally dependent on the TCR/CD3 complex in human T cells FASEB J. 1998-05-01 [PMID: 9576485] (In vitro, Human)	In vitro	Human
Deaglio S, Morra M, Mallone R et al. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member J Immunol. 1998-01-01 [PMID: 9551996] (FLOW, Human)	FLOW	Human
Sorensen EM Plasma-derived exosomes as potential biomarkers for pediatric acute leukemia. Thesis 2020-01-01 (WB, Human) Details: Exosomes from human plasma samples underwent Western blot analysis.	WB	Human
Wang X, Nakamoto T, Dulinska-Molak I. Regulating the stemness of mesenchymal stem cells by tuning micropattern features. J Mater Chem B 2020-04-09 [PMID: 32262807]
Show All 11 Publications. Collapse Publications.

Images	Ratings	Applications	Species	Date	Details
	5 reviewed by: Verified Customer	ICC	Human	12/15/2021	View Summary Application Immunocytochemistry Sample Tested Non-Hodgkin's lymphoma cells Species Human Lot CB19

Array NBP2-25196

• CD19 Antibodies
• CD19 Antibody Pairs
• CD19 ELISA Kits
• CD19 Lysate
• CD19 Protein
• CD19 Proteins and Enzymes